Cell Therapy: Parkinson’s Disease

Treatment for Parkinson’s disease will be an area in the Cell Therapy field StemBios’ SB Cells^® can be utilized. Parkinson’s disease is the result of degeneration of neurons in the brain created by a shortage of the neurotransmitter, dopamine.

Figure 8. SB-3 differentiation into Ectoderm: Stained with Anti-Neurofilament Ab 200X

The traditional treatment for Parkinson’s is the use of L-DOPA therapy increasing dopamine levels. The side effects of this treatment include nausea, vomit, visual and auditory hallucination, brownish saliva and urine. Our research has shown that StemBios’ SB-3 and SB-4 cells have the capability to differentiate into tyrosine hydroxylase and GFAP positive neuronal cells (Figure 8). Compared to the current traditional treatment for Parkinson’s, our SB-3 and SB-4 cells may prove to have an advantage as the cells are easily obtained from a patient’s own bone marrow or blood and therefore, will not result in immune rejection.